title: Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.
abstract: In China, no data are available to evaluate the interchangeability between Chinese domestic inactivated hepatitis A vaccines (Healive) and imported inactivated hepatitis A vaccines (Havrix). A double-blind, randomized controlled study was to compare interchangeability and safety of Healive and Havrix among Chinese children. Vaccine was administered to 303 healthy children at 0 and 6 months in one of four vaccine regimens: Healive-Healive; Healive-Havrix; Havrix-Healive or Havrix-Havrix. We collected sera samples at 0 (before vaccination), 6 (before second dose) and 7 months (after second dose), and compared groups in terms of proportion of sero-conversions which is defined as ≥ 20 mIU/ml, and geometric mean concentrations (GMCs) of anti-hepatitis A virus (HAV) antibody. Seroconversion rates were 133/133 (100%) for those received one dose of Healive and 105/131 (80.2%) for those received one dose of Havrix at 6 months, respectively (P<0.001), GMCs for Healive and Havrix were 126.1 and 40.9 mIU/ml (P<0.001), respectively. At 7 months, the seroconversion rate was 100% among all groups. The GMC after two doses of Healive was 8905.5 mIU/ml compared with 1900.9 mIU/ml after two doses of Havrix (P<0.001). The GMC in the Healive-Havrix group was 3275.8 mIU/ml compared with 4165.8 mIU/ml in the Havrix-Healive group (P=0.058). There is not different of reported adverse reactions across the groups. The present study indicated that both vaccines can be recommended for interchangeable using of immunization among Chinese healthy children.
authors.affiliation: Tianjing Municipality Center for Disease Control and Prevention, Tianjing, China.
authors.forename: Zhi-Lun
authors.initials: ZL
authors.lastname: Zhang
authors.forename: Xiang-Jun
authors.initials: XJ
authors.lastname: Zhu
authors.forename: Xu
authors.initials: X
authors.lastname: Wang
authors.forename: Miao
authors.initials: M
authors.lastname: Liang
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Gao
authors.forename: Jun-Yu
authors.initials: JY
authors.lastname: Wu
authors.forename: Xiao-Jing
authors.initials: XJ
authors.lastname: Dong
authors.forename: Rong-Kai
authors.initials: RK
authors.lastname: Liu
authors.forename: Jiang-Ting
authors.initials: JT
authors.lastname: Chen
authors.forename: Yuan-Quan
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Zhang
authors.forename: Weidong
authors.initials: W
authors.lastname: Yin
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002681:China; D004311:Double-Blind Method; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D006805:Human Experimentation; D006801:Humans; D007223:Infant; D008297:Male; D014611:Vaccination / Q000379:methods*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated